TARX (Tarsier Pharma) DeferredTaxAndRevenue: $0.00 Mil (As of Dec. 2025)


What is Tarsier Pharma DeferredTaxAndRevenue?

Tarsier Pharma TARX DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2025.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Tarsier Pharma's current deferred tax and revenue for the quarter that ended in Dec. 2025 was $0.00 Mil.

Tarsier Pharma DeferredTaxAndRevenue Related Terms

Tarsier Pharma DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma DeferredTaxAndRevenue Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
DeferredTaxAndRevenue
0.00 0.00 0.00

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
Tarsier Pharma (TARX) has a DeferredTaxAndRevenue of $0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Tarsier Pharma.
Is Tarsier Pharma's DeferredTaxAndRevenue too high?
Tarsier Pharma's current DeferredTaxAndRevenue is $0.00 Mil.
How does Tarsier Pharma's DeferredTaxAndRevenue compare to ?
Tarsier Pharma's DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Tarsier Pharma. Tarsier Pharma's current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsier Pharma stock overvalued right now?
Tarsier Pharma (TARX) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Tarsier Pharma (TARX), the current DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.